Molecular Vision partners on companion diagnostic device      

Molecular Vision has signed a contract with a leading European specialty pharmaceutical company to develop a point-of-care companion diagnostic device for the company’s diagnostic compound.

Based on the BioLEDTM platform, the device will have ability to test multiple samples through measurement of the light signal changes associated with one or several optical parameters in biological assays.
The program will take the companion diagnostic device through initial prototyping and optimisation phases before moving on to manufacturing development, validation and market launch.

Chris Hand, CEO of Molecular Vision, said: “This partnership validates Molecular Vision’s proprietary technology platform, which has the potential to address the growing demand for faster, more accurate, point-of-care diagnostic tests. It also exemplifies the pharmaceutical industry’s increased focus on developing personalised medicines, where companion diagnostic tests can help improve and guide treatment options and so help reduce healthcare costs.”